By Isabel Demetz (Reuters) -Swiss contract drugmaker Lonza plans to simplify its structure and exit its capsules and health ...

Swiss contract drugmaker Lonza plans to exit its capsules and health ingredients (CHI) business, it said on Thursday, after ...

With a new CEO at the helm, Swiss CDMO Lonza is looking to revivify its business by doubling down on contract manufacturing ...

Lonza Group AG / Key word (s): Strategic Company Decision Lonza Investor Update 2024 Outlines Strategy, New Organizational Structure and Guidance 12-Dec-2024 / 06:25 CET/CEST Release of an ad hoc ...

Swiss healthcare manufacturing organization Lonza saw its shares rise 7% to 559.40 francs in early trading, as it announced ...

Lonza Group Ltd (GB:0QNO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

Investing.com -- Lonza’s shares rose over 6% on Thursday following the company’s announcement of plans to divest its Capsules ...

Recent developments in the health sector include a dosing pause in Keros Therapeutics' drug trial, Corcept Therapeutics' ALS ...

Delivering biologics via oral administration represents a growing market that is expected to exhibit 35% CAGR from 2023–2028.

Lonza Group AG (OTCMKTS:LZAGY – Free Report) – William Blair lowered their FY2025 EPS estimates for Lonza Group in a research ...

Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development ...